Skip to main content

Skysona Side Effects

Generic name: elivaldogene autotemcel

Medically reviewed by Drugs.com. Last updated on Dec 10, 2023.

Note: This document contains side effect information about elivaldogene autotemcel. Some dosage forms listed on this page may not apply to the brand name Skysona.

Applies to elivaldogene autotemcel: intravenous suspension.

Warning

Intravenous route (Suspension)

Hematologic malignancy, including life-threatening cases of myelodysplastic syndrome, has occurred in patients treated with elivaldogene autotemcel. Patients have been diagnosed between 14 months and 7.5 years after elivaldogene autotemcel administration, and the cancers appear to be the result of the elivaldogene autotemcel lentiviral vector, Lenti-D, integration in proto-oncogenes. Monitor patients closely for evidence of malignancy through complete blood counts at least every 6 months and through assessments for evidence for clonal expansion or predominance at least twice in the first year and annually thereafter; consider bone marrow evaluations as clinically indicated.

Serious side effects of Skysona

Along with its needed effects, elivaldogene autotemcel (the active ingredient contained in Skysona) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking elivaldogene autotemcel:

More common

Incidence not known

Other side effects of Skysona

Some side effects of elivaldogene autotemcel may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to elivaldogene autotemcel: intravenous suspension.

Cardiovascular

Very common (10% or more): Tachycardia (15%)[Ref]

Dermatologic

Very common (10% or more): Alopecia (72%), pruritus (19%), rash (21%), skin hyperpigmentation (18%)[Ref]

General

The most common serious adverse reactions (with 3% or greater incidence) that were observed in 54% patients included febrile neutropenia, pyrexia (fever), seizure, myelodysplastic syndrome, pseudomonal bacteremia, pancytopenia, vascular device infection, mucositis, and vomiting.[Ref]

Hematologic

Very common (10% or more): Febrile neutropenia (73%), hypertension (12%)[Ref]

Grade 3 or 4 laboratory hematologic abnormality that occurred in more than 40% of patients were leukopenia, lymphopenia, thrombocytopenia, neutropenia, anemia, and hypokalemia.[Ref]

Local

Very common (10% or more): Transfusion reaction (12%)[Ref]

Metabolic

Very common (10% or more): Decreased appetite (64%)[Ref]

Nervous system

Very common (10% or more): Anxiety (15%), headache (28%)[Ref]

Ocular

Very common (10% or more): Vision blurred (10%)[Ref]

Other

Very common (10% or more): Pyrexia (36%)[Ref]

Respiratory

Very common (10% or more): Cough (10%), epistaxis (19%), oropharyngeal pain (18%)[Ref]

References

1. Product Information. Skysona (elivaldogene autotemcel). bluebird bio. 2022.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.